APPA is the quality PDUFA play, with an excellent chance of approval, a very large CINV market, and high liklihood for a buyout following approval.
Somaxon on the other hand, is a POS (IMO), in spite of the stock's recent move. Their drug Silenor has two CRLs already (complete response letters), and the FDA has said that Silenor lacks the 'robustness' needed for approval. But Feuerstein listed them today in his March 'event' calender, so it'll get some attention until people do their DD. The pump/dump outfit BioMedReports is pushing Somaxon, so that should tell you something.